#23 · Proteomics
Proteomics nominates cancer targets across cryptic peptides and signaling networks
The items share a cancer target-identification theme rather than a single mechanism. RyboCypher links dark RNA isoforms to MS/MS data, producing CypherAtlas with about 80,000 cryptic peptides and a cancer-linked YBX1 target (preprint). A published deep learning screen of more than 6,000 repurposed compounds nominates emodepside, which inhibits triple-negative breast cancer xenograft growth via NAMPT. INSIGHT couples cell sorting with mass spectrometry to map in vivo phosphoproteomic signaling networks of disseminating glioblastoma cells. The new element is the expansion of target space: peptides from noncanonical transcripts, a computationally prioritized drug candidate, and signaling states measured directly in vivo. The deep learning screen is computational rather than mass spectrometry-based, so the common thread is proteomic and computational evidence applied to cancer target discovery.
Published papers
Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer.
Deep learning screen of 6,000+ repurposed compounds nominates emodepside, which inhibits TNBC xenograft growth via NAMPT.
Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT.
INSIGHT couples cell sorting with mass spectrometry to map in vivo phosphoproteomic signaling networks of disseminating glioblastoma cells from patient-derived…
Preprints
Discovery and Targeting of a Cryptic Human Proteome
RyboCypher links dark RNA isoforms to MS/MS data, producing CypherAtlas with ~80,000 cryptic peptides and a cancer-linked YBX1 target.
Topic history
| Date | Rank |
|---|---|
| #23 |